Skip to main content
. 2021 Dec 15;131(24):e140436. doi: 10.1172/JCI140436

Figure 7. Combinatory therapy with I3C improves the efficacy of PI3K inhibitors.

Figure 7

(A–C) Tumor xenograft assays were performed with subcutaneous implantation of MDA-MB-231 parental cells. Mice were treated orally with vehicle, BKM120 (30 mg/kg), I3C (100 mg/kg), or a combination of the drugs every day starting on day 3 after implantation. Data are shown as the mean ± SEM for size and the mean ± SD for weight (n = 8 per group). (D–F) Analysis of the size and weight of xenografts of resistant MDA-MB-231 HD cells. Mice were treated with the indicated drugs at the same dose as that used in the parental cells starting on day 3 after implantation (n = 8 per group). Data are shown as the mean ± SEM for size and mean ± SD for weight. *P < 0.05, **P < 0.01, and ***P < 0.005, by linear mixed-effects model (A and D) and 1-way ANOVA followed by Tukey-Kramer multiple-comparison test (B and E).